Harrow Provides TRIESENCE® Relaunch Update
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
Harrow to Present at Two Investor Conferences in May
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
Harrow Announces First Quarter 2024 Financial Results
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results
Harrow Licenses Canadian Rights to Apotex for Ophthalmic Products
Harrow Announces New Appointments to its Board of Directors
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%